Companies › Beijing Dongfang Biotech
1 active drug program in 3 registered trials: 3 Phase 3; Metabolic and endocrine; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| JY09 (1.2mg) Exendin-4 Fc fusion protein; GLP-1 receptor agonist | GLP1R | Phase 3 | Type 2 Diabetes Mellitus; Type2 Diabetes Mellitus | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06254014 | JY09 (1.2mg) | Phase 3 | Type 2 Diabetes Mellitus | Metabolic and endocrine | May 2026 |
| NCT06257966 | JY09 (1.2mg) | Phase 3 | Type2 Diabetes Mellitus | Metabolic and endocrine | Nov 2026 |
| NCT06257966 | JY09 (1.2mg) | Phase 3 | Type2 Diabetes Mellitus | Metabolic and endocrine | Nov 2026 |
Verdiva Bio Dev Chendu DIAO Pharmaceutical Group Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Kailera Actimed Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.